News

  • 31 October 2011

    FDA approves Mylan pain drug

    Mylan's abbreviated new drug application for morphine sulphate extended-release tablets has been approved by the US Food and Drug Administration (FDA) .

  • 30 October 2011

    Biotie and Merck turn their backs on Newron

    Finland’s Biotie Therapies has pulled out of its planned merger with Newron Pharmaceuticals following a decision by Merck to return the full global rights to investigational Parkinson's disease drug safinamide...

  • 30 October 2011

    Bristol-Myers Squibb reports strong revenue rise

    Bristol-Myers Squibb (BMS) has reported strong third quarter results, announcing an 11% increase in revenue to $5.35bn attributed to the company’s blood thinning drug Plavix.

  • 30 October 2011

    Bionovo commences Menerba drug Phase 3 trial

    Biotech company Bionovo has begun a Phase 3 clinical trial designed to assess the safety and efficacy of two doses of oral estrogen receptor beta (ER-b) selective drug, Menerba (MF101),...

  • 30 October 2011

    KemPharm to develop new pain therapy

    KemPharm is planning to initiate the development of KP511, an oral prodrug of hydromorphone that is used to manage pain in patients where an opioid analgesic is appropriate.

  • 27 October 2011

    Basilea completes BAL30072 antibiotic trial

    Basilea Pharmaceutical has completed a Phase I study to test the efficacy of its novel sulfactam antibiotic BAL30072 as a treatment of multi-drug resistant Gram-negative infections.

Close
Close
Close

Go Top